Charles Bennett to Disease-Free Survival
This is a "connection" page, showing publications Charles Bennett has written about Disease-Free Survival.
Connection Strength
0.244
-
Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis. Bone Marrow Transplant. 2016 Feb; 51(2):277-82.
Score: 0.116
-
Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology. 2001 Apr; 57(4):727-32.
Score: 0.042
-
Interpretation of surrogate endpoints in the era of the 21st Century Cures Act. BMJ. 2016 Dec 30; 355:i6286.
Score: 0.032
-
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol. 2007 Jun; 137(6):545-52.
Score: 0.016
-
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007 Apr 20; 25(12):1596-605.
Score: 0.016
-
Pilot study of a utilities-based treatment decision intervention for prostate cancer patients. Clin Prostate Cancer. 2002 Sep; 1(2):105-14.
Score: 0.012
-
Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000 Apr 04; 132(7):566-77.
Score: 0.010